Abstract
BackgroundImmune checkpoint inhibitors (ICIs) have been used to treat many distinct cancers, including non-small cell lung cancer (NSCLC). Better tools are needed to predict which patients will benefit from ICI...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have